Page 48 - Solid Tumors News Today

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancerBiomarker studies shed light on patient characteristics driving improved response to PD-(L)1 inhibitorsCAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS W...

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

- Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones - - SerpinPC registration studies planned to begin in 2H 2022 following

30.03.2022 - – Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on ...

Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights - read this article along with other careers information, tips and advice on BioSpace

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) was the recipient of unusually large options trading activity on Friday. Stock traders acquired 2,610 call options on the stock. This is an increase of approximately 1,137% compared to the average volume of 211 call options. Several hedge funds and other institutional investors have recently added to or […]

The 17th Annual Garnet E. Peck Symposium will be held April 7 by the Department of Industrial and Physical Pharmacy with corporate support from Aprecia, Catalent Biologics and MED Institute. The symposium will be held on the second floor of Stewart Center.